Complete patients recruitment for Cervicitis 2005.06.08

 
(Hong Kong, 8 June 2005) - Lee's Pharmaceutical Holdings Limited (GEM) Stock: 8221; Website: www.leespharm.com) today announced that the Group has successfully completed the recruitment of patients for a clinical trial on Yallaferon®("Recombinant Human Interferon α-2b gel"), its flagship product for cervicitis.

This clinical study was designed to assess safety, tolerability and effective of Yallaferon® for the treatment of patients with cervicitis and cervical erosion. This multi-centers, randomized double-blind, placebo-controlled clinical trial, involving 320 patients was initiated in September 2004. The trial was conducted at eight leading hospitals in three major cities of the PRC, namely Beijing, Shanghai and Guangzhou....
 


© Lee's Pharmaceutical Holdings Limited     Terms of Use   |   Privacy Statement Designed by YSD